Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype (p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors / Minari, R.; Bonatti, F.; Mazzaschi, G.; Dodi, A.; Facchinetti, F.; Gelsomino, F.; Cinquegrani, G.; Squadrilli, A.; Bordi, P.; Buti, S.; Bersanelli, M.; Leonetti, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Quaini, F.; Ardizzoni, A.; Tiseo, M.. - In: TUMORI. - ISSN 0300-8916. - (2021), p. 030089162110149. [10.1177/03008916211014954]

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors

Minari R.;Bonatti F.;Mazzaschi G.;Facchinetti F.;Cinquegrani G.;Bordi P.;Buti S.;Bersanelli M.;Leonetti A.;Quaini F.;Tiseo M.
2021

Abstract

Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association (p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype (p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors / Minari, R.; Bonatti, F.; Mazzaschi, G.; Dodi, A.; Facchinetti, F.; Gelsomino, F.; Cinquegrani, G.; Squadrilli, A.; Bordi, P.; Buti, S.; Bersanelli, M.; Leonetti, A.; Cosenza, A.; Ferri, L.; Rapacchi, E.; Quaini, F.; Ardizzoni, A.; Tiseo, M.. - In: TUMORI. - ISSN 0300-8916. - (2021), p. 030089162110149. [10.1177/03008916211014954]
File in questo prodotto:
File Dimensione Formato  
Manuscript_Minari et al MT.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 233.41 kB
Formato Adobe PDF
233.41 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2901109
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact